Dacomitinib — Drug Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

3 Recruiting

0 Completed trials

3 Sponsors

4 Countries

Phase III

Phase II

Phase III: 1 Phase II: 2

Oversight events:

1 serious breach across 1 trial

Indications tested

3 total

A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s… Recruiting

2024-518223-29-00 Phase II 2 countries Fondazione Ricerca Traslazionale
ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study Recruiting

2024-518172-31-01 Phase III 1 country Region Skane
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Showing 1–3 of 3 trials